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Abstract
Background:  Enterovirus 71 (EV71) is a major causative viral agent responsible for large
outbreaks of hand, foot and mouth disease (HFMD), a common rash illness in children and infants.
There is no effective antiviral treatment for severe EV71 infections and no vaccine is available. The
objectives of this study were to design and construct a DNA vaccine against Enterovirus 71 using
the viral capsid protein (VP1) gene of EV71 and to verify the functionality of the DNA vaccine in
vitro and in vivo.
Methods: The VP1 gene of EV71 from two local outbreak isolates were amplified using PCR and
then inserted into a eukaryotic expression vector, pVAX1. The 3.9 kb recombinant constructs
were transformed into competent E. coli cells and the positive clones were screened and selected
using PCR analysis, restriction digestion analysis and DNA sequencing. The constructs were then
tested for protein expression in Vero cells. Subsequently, in the in vivo studies, female Balb/c mice
were immunized with the DNA vaccine constructs. Enzyme Linked Immunosorbent Assay (ELISA)
and virus neutralizing assay were performed to detect the presence of anti-VP1 IgG in mice and its
neutralizing effect against the EV71.
Results: The pVAX1 vector was successfully cloned with the VP1 gene from each of the isolate
(S2/86/1 and 410/4) in the correct orientation and in-frame. The DNA vaccine constructs with the
VP1 gene were shown to be expressed in a cell-free in vitro expression system. The VP1 protein
was successfully expressed in the mammalian cell line and was detected using RT-PCR, Indirect
Immunofluorescence Assay (IFA) and western blotting. The anti-VP1 IgG levels in mice immunized
with the DNA vaccine constructs increased after the first booster but declined following the
second booster. The anti-VP1 IgG in the mice immunized with the DNA vaccine constructs
exhibited neutralising activity against EV71.
Conclusion: The promising results obtained in the present study have prompted further testing
to improve the expression and immunogenicity of this potential EV71 DNA vaccine.
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1. Background
Enterovirus 71 (EV71) belongs to the genus of enterovi-
ruses from the family Picornaviridae. It possesses a single
stranded RNA genome of approximately 7500 nucleotides
of positive polarity, which is encapsulated in a capsid con-
taining 60 copies of each of the four structural proteins,
VP1 through VP4 [1]. The antigenic diversity among the
enteroviruses is caused by variations within capsid pro-
teins VP1 to VP3, but neutralization epitopes are most
densely clustered on VP1 [2].
Enterovirus 71, along with coxsackievirus A16 (CA16), is
a major causative viral agent responsible for large out-
breaks of hand, foot and mouth disease (HFMD), a com-
mon rash illness in children and infants. EV71 is thought
to spread by contact with fecal contaminated materials.
Infection by the virus is often asymptomatic or may man-
ifest as mild self-limiting illness which is often character-
ized by the presence of characteristic lesions on the palms,
soles and oral mucosa. EV71 and CA16 are genetically
closely related. However, unlike CA16 that is more lim-
ited in its pathogenicity to HFMD, EV71 is also associated
with severe complications involving the central nervous
system (CNS) such as aseptic meningitis, encephalitis and
poliomyelitis-like paralysis [3,4].
Since the first report of EV71 infection which occurred in
California in 1969 [5], world-wide reports of outbreaks
have followed. The neurovirulence of EV71 first came to
attention in 1975 in Bulgaria when 44 people died of a
polio-like disease [6]. Epidemics of EV71 causing CNS dis-
eases subsequently occurred in New York, Australia,
Europe and Asia [7-10]. An unusual epidemic of HFMD
complicated by fatal myocarditis and pulmonary edema
occurred in Malaysia in 1997, and EV71 had been impli-
cated as the etiology of the outbreak [11]. Thirty-one chil-
dren in Sarawak, Malaysia and four children in Peninsular
Malaysia succumbed to the infection within hours of
admission to the hospitals [12]. The largest EV71 epi-
demic reported to date occurred from April to December
of 1998 in Taiwan in which a variety of clinical manifesta-
tions were observed. These included HFMD, encephalitis,
meningitis, herpangina and poliomyelitits-like paralysis.
In this outbreak, more than 90,000 children infected with
HFMD were reported. Among these patients, more than
320 children were hospitalized with suspected meningitis,
encephalitis, or acute flaccid paralysis, and at least 55
died, suggesting neurovirulence of the pathogen [13].
There is no effective antiviral treatment for severe EV71
infections and no vaccine is available. Thus, the only cur-
rent means to prevent EV71 infection is through avoid-
ance of contact between infected and susceptible
individuals [14]. Since no effective antiviral agents are
available, the need for an effective EV71 vaccine is urgent
to immunize the public before an outbreak occurs. A for-
malin-inactivated EV71 vaccine was developed in
response to the Bulgarian epidemic in 1975 [6,15] but
was not used to control the epidemic and has not been
used since. Thus, no data on the efficacy of the Bulgarian
vaccine is available. Recently, several candidates of EV71
vaccines using different approaches are being investi-
gated. These include formalin-inactivated whole virus vac-
cine, DNA vaccine and recombinant protein vaccine.
These vaccine constructs remain promising vaccine strate-
gies that require further refinement, thus further study and
development are required [16-18].
In this study, a DNA vaccine encoding the VP1 gene of
EV71 was designed and constructed. This vaccine candi-
date was tested in vitro for expression of VP1 protein in
mammalian cell culture and followed by in vivo testing of
the ability for the protein to be expressed and to elicit an
immune response in mice.
2. Materials and methods
2.1 Construction and validation of DNA vaccine
The VP1 gene of EV71 isolate 410/4 (genotype B4) and
EV71 isolate S2/86/1 (genotype B4) which have been
cloned into pCR® Blunt Vector (Zero Blunt™ PCR Cloning
Kit, Invitrogen) were provided by Prof. Mary Jane Car-
dosa, Universiti Malaysia Sarawak (UNIMAS). The VP1
gene of both isolates was amplified by polymerase chain
reaction (PCR). A forward primer 5'-GATCTGCAG-
GCCACCATGGGGGATAGAGTGGCAGATG-3' and a
reverse primer 5'-GAAGCGGCCGCCTAAAGGGTAG-
TAATGGCAGTACG-3' were used to amplify the VP1 gene
of EV71 isolate 410/4, whereas a forward primer 5'-
GATCTGCAGGCCACCATGGGAGATAGAGCGGCA-
GATG-3' and a reverse primer 5'-GAAGCG-
GCCGCCTAAAGGGTAGTAATGGCAGTACG-3' were
used to amplify the VP1 gene of EV71 isolate S2/86/1. The
Pst I site and Not I site (underlined) were included in the
forward and reverse primers, respectively for the purpose
of cloning. The PCR temperature profile included dena-
turation at 95°C for 5 min, followed by 30 cycles of dena-
turation at 95°C for1 min, annealing at 62°C and
extension at 72°C for 1 min 20s, followed by 10 min of
heating at 72°C. The PCR products were then purified and
subjected to automated sequencing for confirmation.
Subsequently, the amplified VP1 gene was digested with
Pst I and Not I and ligated with the pVAX1 vector. The
pVAX1/VP1 plasmid was transformed into One Shot® TOP
10 Chemically Competent Cells (Invitrogen).
2.2 Detection of cell-free in vitro expression of VP1 protein
The Transcend™ Non-Radioactive Translation Detection
Systems (Promega, U.S.A.) was used to detect the VP1 pro-
teins synthesized in vitro. Biotinylated lysine residues are
incorporated into nascent proteins during translation in aGenetic Vaccines and Therapy 2007, 5:6 http://www.gvt-journal.com/content/5/1/6
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cell-free single-tube, coupled transcription/translation
reaction for eukaryotic in vitro protein expression. After
running SDS-PAGE and electroblotting, the biotinylated
VP1 proteins can be visualised by binding to Streptavidin-
Horseradish Peroxidase, followed by chemiluminescent
detection.
2.3 In-vitro protein expression in eukaryotic cells
Vero cells (ATCC CCL-81) were cultured in RPMI 1640
with 10% fetal calf serum added until growth reach 80%
confluence. Lipofectamine™ 2000 (Invitrogen) was used
to transfect the DNA vaccine constructs following the
manufacturer's instruction. The negative control experi-
ment was performed using the backbone vector, pVAX1.
The transfected cells were incubated at 37°C in a 5% CO2
incubator for 48 hours before detection of VP1 gene
expression was carried out.
2.4 Detection of VP1 mRNA
The expression of VP1 gene was determined by detecting
the presence of VP1 mRNA using RT-PCR. Isolation of
total RNA from the transfected cultured cells was per-
formed using SV Total RNA Isolation System (Promega).
RETROscript™ kit (Ambion) was used to reverse transcribe
the extracted RNA into its complementary DNA sequence
(cDNA). The cDNA was used as template for the amplifi-
cation of VP1 gene using PCR method as described in 2.1.
The PCR products were subjected to agarose gel electro-
phoresis to detect the presence of VP1 gene.
2.5 Indirect Immunofluorescence Assay (IFA)
Light Diagnostic Enterovirus 71 Monoclonal Antibody
(Chemicon International, CA, USA) was used to detect the
VP1 protein expressed in cell culture using an indirect
immunofluorescence assay (IFA). Briefly, the transfected
cells were removed after 48 hours of incubation and resus-
pended in PBS to make cell spots on microscope slides.
The slides were fixed in chilled (2–8°C) acetone for 10
minutes. Sufficient Enterovirus 71 Monoclonal Antibody
was added to cover the cells on the slides and incubated at
37°C for 30 minutes in an incubator. The slides were
washed gently with PBS and then added with sufficient
anti-mouse IgG: FITC (Chemicon International, CA, USA)
to cover the cells. Subsequently, the slides were mounted
with cover slips and examined using a fluorescence micro-
scope (DMRA2, Leica).
2.6 Western blot
After 72 hours of incubation, the transfected cells were
harvested and protein isolation was carried out using
Mammalian Protein Extraction Reagent (Pierce, U.S.A.).
The protein samples were loaded onto a discontinuous
SDS-polyarylamide gel with 5% stacking gel and 12.5%
separating gel. Electrophoresis was performed using Mini-
PROTEAN® III Electrophoresis Cell (Bio-Rad, U.S.A.). Sub-
sequently, the protein bands were electrophoretically
transferred from the SDS-polyacrylamide gel to PVDF
membrane using a Mini Trans-Blot® Electrophoretic Trans-
fer Cell (Bio-Rad, U.S.A.). The VP1 protein was detected
using rabbit anti-EV71 polyclonal antibody and alkaline
phosphatase conjugate chicken anti rabbit secondary anti-
body (Chemicon, U.S.A.).
2.7 DNA vaccination of BALB/c mice
Ethical approval to work with animals was obtained from
the Animal Care and Use Committee (ACUC), Faculty of
Medicine and Health Sciences, UPM. Female Balb/c mice
aged between 6–8 weeks with 19–21 gm weight were
divided in groups of 6 and were immunised by intramus-
cular injection with each of the DNA vaccine constructs:
pVAX1/VP1-4, pVAX1/VP1-S or pEGFPN-1/VP1 (EV71
VP1-expresing vector which was provided by Prof. Dr.
Sazaly Abu Bakar, University of Malaya and served as a
control). The mice were injected with 100 μl of the plas-
mid DNA solution in phosphate buffered saline (PBS) at
a concentration of 100 μg per mouse. The two negative
control groups, each with 6 mice, were injected with the
backbone vector pVAX1 (100 μg per mouse) and PBS
(100 μl per mouse). The animals were given food and
water ad lib. The mice in each group were given booster
injections at 14 and 28 days post-immunisation. Blood
samples were collected from the mice by cardiac puncture
at day 0, day 14, day 28 and day 42 of experiment.
2.8 Enzyme Linked Immunosorbent Assay (ELISA)
To detect the presence of anti-VP1 IgG in the sera of
immunised mice, Enzyme Linked Immunosorbent Assay
(ELISA) was performed using ELISA Reagent Kit (Chemi-
con International, U.S.A.) and 96-well microtiter plates
coated with VP1 fusion protein and S. tag protein (nega-
tive control). Optical density (O.D.) was read at 450 nm
using an ELISA reader. The adjusted O.D. of each sample
was calculated by subtracting the mean O.D. of the con-
trol well from the mean O.D. of VP1 antigen well. Statis-
tical analysis of the adjusted O.D. between the different
groups immunized with DNA vaccines and negative con-
trols was performed using one-way ANOVA test.
2.9 Virus neutralizing assay
The virus neutralisation test was performed to assess the
ability of the mice serum to neutralise the live enterovirus
71. A positive serum from an EV71-infected child (pro-
vided by Prof. Dr. Sazaly Abu Bakar, University Malaya)
was used as a positive serum control in this test. The test
was carried out using the pooled mice sera of each group
(pVAX1/VP1-S, pVAX1/VP1-4, pVAX1 and PBS) collected
on day 14. Vero cells were seeded in 96-well plates at a
density of 1 × 105 cells/well in RPMI supplemented with
10% FBS and incubated overnight. To perform the neu-
tralisation test, the mice sera samples were first incubatedGenetic Vaccines and Therapy 2007, 5:6 http://www.gvt-journal.com/content/5/1/6
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at 56°C for 30 minutes to inactivate the complement. A
two-fold serial dilution (from 1:2 to 1:64) was carried out
by diluting the test mice serum with RPMI medium with-
out FBS. Subsequently, 80 μl of each diluted test serum
sample was added with 80 μl of 1 × 103 p.f.u. of live EV71
(1:1 ratio) and incubated for 1 hour at 37°C. All the tests
were performed in triplicates. Then, the Vero cells were
washed with 1 × PBS and incubated with 50 μl inoculum
of test serum-virus mixture per well at room temperature
for 1 hour. Virus control wells were included as negative
controls in the test where the cells were incubated with
only live virus that have not been treated with any serum.
After incubation, the cells were added with 200 μl of RPMI
supplemented with 5% FBS per well and incubated in cell
culture CO2 incubator at 37°C with 5% CO2 for 3 days.
The cytopathic effect (CPE) of cells and the number of
plaques formed were monitored under an inverted tissue
culture microscope (Olympus CK40, Japan). The titre was
read as the highest dilution that resulted in more than
50% CPE.
3 Results
3.1 Construction of DNA vaccine
The amplification of VP1 gene for both isolates produced
a 923 bp band as shown in Figure 1. Each amplicon (VP1
gene) had been designed to include the Pst I site and Not
I site at both ends to facilitate cloning into expression vec-
tor, pVAX1 (Invitrogen, U.S.A.). The PCR products were
purified using QIAquick Gel Extraction Kit (Qiagen, Ger-
many) and sent for sequence analysis. The sequencing
results confirmed that the amplicons are the VP1 gene of
EV71.
The VP1 gene was successfully cloned into the eukaryotic
expression vector, pVAX1 and transformed into One Shot®
TOP 10 Chemically Competent Cells (Invitrogen). The
Amplification of VP1 genes of EV71 isolate S2/86/1 and isolate 410/4 by PCR Figure 1
Amplification of VP1 genes of EV71 isolate S2/86/1 and isolate 410/4 by PCR. Lane M shows a 1 kb molecular 
marker (Fermentas). Lane 1 and lane 3 each shows a band of size 923 bp, which represent the PCR product of VP1 gene of 
EV71 isolate S2/86/1 and isolate 410/4, respectively. Lane 2 and lane 4 which show no band of PCR product are PCR negative 
controls that used water as template.
1000 bp 
   M         1        2    3        4
750 bp 
923 bp Genetic Vaccines and Therapy 2007, 5:6 http://www.gvt-journal.com/content/5/1/6
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positive clones that carried the pVAX1/VP1 DNA vaccine
were screened and selected using PCR and restriction
digestion analysis. The desired constructs were further
confirmed by automated DNA sequencing. The pVAX1
vector that was successfully cloned with VP1 gene of each
EV71 isolate S2/86/1 and isolate 410/4, in the correct ori-
entation and in frame were designated as pVAX1/VP1-S
and pVAX1/VP1-4, respectively.
The DNA vaccine constructs were verified for VP1 gene
expression using a cell-free in vitro expression system,
TNT®  Quick Coupled Transcription/Translation System
(Promega. U.S.A.). The biotinylated lysine residues were
incorporated into the VP1 protein during translation.
Using the chemiluminescent detection method with
streptavidin-alkaline phosphatase in Western blotting, a
protein band with a size of 36 kD was obtained in each
transcription/translation reaction of pVAX1/VP1-S and
pVAX1/VP1-4 which indicated the translated VP1 protein
(Figure 2, lanes 1 and 2). There was no protein band
observed in the reaction sample of backbone vector
pVAX1 (Figure 2, lane 3) since it did not contain any cod-
ing sequence.
Western blot analysis on eukaryotic cell-free in vitro expression of VP1 Protein using Transcend™ Chemiluminescent Transla- tion Detection Systems (Promega, U.S.A.) Figure 2
Western blot analysis on eukaryotic cell-free in vitro expression of VP1 Protein using Transcend™ Chemilumi-
nescent Translation Detection Systems (Promega, U.S.A.). Lane M shows a prestained protein molecular weight 
marker (Fermentas, Lithuania). Lane 1 to lane 4 represent the eukaryotic cell-free in vitro transcription/translation reactions of 
pVAX1/VP1-S, pVAX1VP1-4, pVAX1 and Luciferase T7 control DNA respectively. Lane 1 and lane 2 each shows a band of size 
36 kD, indicating the translated VP1 protein. Lane 3 shows no band of translation product with using backbone vector pVAX1 
alone. Lane 4 shows a band of size 61 kD, indicating the translated luciferase protein, which serve as a positive control for the 
eukaryotic cell-free in vitro expression reactions.
 61 kD
       M         1           2     3           4 
86 kD 
47 kD 
36 kD 34 kD Genetic Vaccines and Therapy 2007, 5:6 http://www.gvt-journal.com/content/5/1/6
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3.2 Detection of VP1 mRNA using RT-PCR
A PCR product of expected size 923 bp that represents the
VP1 gene was obtained using cDNA derived from Vero
cells transfected with pVAX1/VP1-S and pVAX1/VP1-4
(Figure 3, lanes 1 and 2, respectively). To eliminate the
possibility that the VP1 PCR product was produced
because of plasmid DNA contamination, T7 forward
primer and BGH reverse primer were used to amplify the
cDNA derived from cells transfected with pVAX1/VP1. No
product was amplified (Figure 3, lanes 5 and 6) since the
T7 forward and BGH reverse priming sites were only
found on pVAX1 vector but not the cDNA that was
derived from the transfected Vero cells. Plasmid DNA
pVAX1 was used as a control for this PCR reaction using
T7 and BGH primers. A PCR product of 176 bp was
obtained (Figure 3, lane 4), indicating that this primer
pair could produce an amplicon from the plasmid DNA
pVAX1. No PCR product was obtained using cDNA
derived from cells transfected with control plasmid, the
backbone vector pVAX1 (Figure 3, lane 3).
3.3 Indirect Immunofluorescence Assay (IFA)
Enterovirus 71 positive and negative control slides
(Chemicon, U.S.A.) were included to assure proper per-
formance of the test. The positive control slide showed
cells exhibiting apple-green fluorescence (Figure 4a).
Apple-green fluorescence signals were detected in the cells
transfected with pVAX1/VP1-S and pVAX1/VP1-4 (Figure
4b and 4c, respectively). The cells transfected with the
backbone vector pVAX1, which served as a negative con-
trol did not exhibit any fluorescence (Figure 4d).
3.4 Western blot
A band of 36 kD was visualised in protein extracts from
cells transfected with pVAX1/VP1-S and pVAX1/VP1-4,
which represents the VP1 protein (Figure 5, lanes 1 and 2,
respectively). No visible band parallel to the VP1 protein
(36 kD) was observed in the cells transfected with back-
bone vector pVAX1 (Figure 5, lane 3) and non-transfected
vero cells (Figure 5, lane 4), which indicated the absence
of VP1 protein in these two samples that served as nega-
tive controls. Extracted protein of enterovirus 71 that
Amplification of VP1 gene by RT-PCR Figure 3
Amplification of VP1 gene by RT-PCR. Lane M shows a 1 kb molecular weight marker (Fermentas, Lithuania). Lane 1 and 
lane 2 each shows a band of size 923 bp, indicating the amplified VP1 gene from extracted mRNA of Vero cells transfected with 
pVAX1/VP1-S and pVAX1/VP1-4 respectively. Lane 3 shows no RT-PCR product amplified from extracted mRNA of Vero cells 
transfected with backbone vector pVAX1 alone, which serve as a negative control. Lane 4 shows the PCR product of size 176 
bp when backbone vector pVAX1 was amplified using T7 forward primer and BGH reverse primer. Lane 5 and lane 6 show no 
PCR product generated from the extracted mRNA of Vero cells transfected with pVAX1/VP1-S and pVAX1/VP1-4 respec-
tively, when using T7 forward primer and BGH reverse primer.
  M 1          2    3         4       5         6 
923 bp
176 bp 
1000 bp 
250 bp Genetic Vaccines and Therapy 2007, 5:6 http://www.gvt-journal.com/content/5/1/6
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served as a positive control produced a 36 kD band of VP1
protein (Figure 5, lane 5).
3.5 Enzyme Linked Immunosorbent Assay (ELISA)
The anti-VP1 IgG elicited in immunised mice sera on day
0, day 14, day 28 and day 42 post-vaccination was meas-
ured using ELISA. There was no significant difference (p >
0.05) between the anti-VP1 IgG responses elicited in all
the mice groups before vaccination, i.e. on day 0 (Figure
6a). The anti-VP1 IgG elicited by pVAX1/VP1-S and
pVAX1/VP1-4 increased to a very significant level (p <
0.001) on day 14 when compared to the negative control
groups (Figure 6b). After the first booster, the anti-VP1
IgG in these two groups continually increased to a level
with the highest OD value (Figure 6c) but subsequently
declined after the second booster although the level was
still statistically significant (p < 0.01) compared to nega-
tive control groups (Figure 6d).
There was no significant increase (p > 0.05) in anti-VP1
IgG level of mice immunized with pEGFPN1/VP1 on day
14 when compared with the level in negative control
Detection of VP1 protein using indirect immunofluorescence assay (IFA) Figure 4
Detection of VP1 protein using indirect immunofluorescence assay (IFA). Expression of VP1 protein in transfected 
vero cells at 48 hours post-transfection was detected by using indirect immunofluorescence assay (IFA). Figure a) shows the EV 
71 positive control slide. Figure b) and c) show vero cells transfected with pVAX1/VP1-S and pVAX1/VP1-4, respectively. Fig-
ure d) shows vero cells transfected with pVAX1.
d) c)
b) a)Genetic Vaccines and Therapy 2007, 5:6 http://www.gvt-journal.com/content/5/1/6
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groups (Figure 6b). The anti-VP1 IgG level of this group
rose after the first booster, but it was not statistically sig-
nificant (p > 0.05) when compared to the negative control
groups (Figure 6c). The level dropped following the sec-
ond booster (Figure 6d).
Overall, the anti-VP1 IgG level in all the three DNA vac-
cine groups (pVAX1/VP1-S, pVAX1/VP1-4 and pEGFPN1/
VP1) increased after the first booster but declined follow-
ing the second booster (Figure 7). A statistically significant
difference between the level of anti-VP1 IgG elicited in
DNA vaccine groups (pVAX1/VP1-S and pVAX1/VP1-4)
and the negative control groups (pVAX1 and PBS) at day
14 (p < 0.001), day 28 (p < 0.01) and day 42 (p < 0.01)
was observed. However, the pEGFPN1/VP1 group did not
show any statistically significant difference (p > 0.05)
compared to the negative control groups.
3.6 Virus neutralisation assay
The virus neutralisation test was used to evaluate the abil-
ity of the DNA vaccine constructs, pVAX1/VP1-S and
pVAX1/VP1-4 to elicit a neutralising antibody response.
By adding live virus to the test serum, the presence of neu-
tralising antibody in the test serum will bind to the virus.
If this occurs, no virus residue will remain to infect the
Vero cells. On the other hand, if there is no neutralising
antibody in the test serum, no antibody will bind to the
virus and the virus will then infect the cells, resulting in
cytopathic effect (CPE). It has been reported that cells
infected with EV71 exhibited a CPE with morphological
changes, including rounding up, shrinkage, cytoplasmic
blebbing, nuclear condensation and detachment from the
culture dish, indicative of apoptotic cells [19]. Similar
CPE was observed in this study.
After 3 days of incubation, all the virus control wells
showed 100% CPE (Figure 8c). Meanwhile, the positive
EV71 infected human serum resulted in almost 100%
Western blot analysis of transfected vero cells at 72 hours post transfection using rabbit anti-VP1 polyclonal antibody Figure 5
Western blot analysis of transfected vero cells at 72 hours post transfection using rabbit anti-VP1 polyclonal 
antibody. Lane M shows a prestained protein molecular weight marker (Fermentas, Lithuania). Lane 1 and lane 2 each shows 
a band of size 36 kD, which represent the expressed VP1 protein in Vero cells transfected with pVAX1/VP1-S and pVAX1/
VP1-4 respectively. Lane 3 and lane 4 represent Vero cells transfected with backbone vector pVAX1 alone and non-transfected 
Vero cells respectively, show no band of size 36 kD, indicating the absence of VP1 protein. Lane 5 represents the extracted 
protein of EV 71, shows a band of size 36 kD, which serve as a positive control.
    M           1             2            3             4            5
47 kD
34 kD
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neutralisation at the dilution of 1:8 to 1:64, where no sign
of CPE was observed, hence demonstrating the neutralis-
ing effect (Figure 8f). At the dilution of 1:2 and 1:4, the
human serum had caused cell death without signs of CPE
where it might be due to the side effect of high serum con-
centration.
The sera of DNA vaccine groups (pVAX1/VP1-S and
pVAX1/VP1-4) had resulted in approximately 50% CPE at
a dilution of 1:32 (Figure 8d and 8e). Only about 15%
and 10% CPE was observed at the dilution of 1:16 and
1:8, respectively. Obviously, the positive EV71 infected
human serum antibody reduced EV71 infectivity much
more effectively, compared with the sera of animals
immunized with DNA vaccines. The sera of negative con-
trol groups, pVAX1 (Figure 8a) and PBS (Figure 8b),
showed no neutralization activity where almost 100%
CPE was observed at all dilutions. The highest dilution of
mice sera that resulted in more than 50% CPE is shown in
Figure 9.
4 Discussion
In the present study, the DNA vaccine encoding the VP1
gene of Enterovirus 71 (EV71) was designed and con-
structed. These DNA vaccine constructs were verified and
tested for in vitro expression of VP1 gene in Vero cell line.
Adjusted OD at 450 nm of ELISA for anti-VP1 IgG of mice serum collected at different days post-immunization at 1:50 dilution Figure 6
Adjusted OD at 450 nm of ELISA for anti-VP1 IgG of mice serum collected at different days post-immunization at 1:50 dilution.
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VP1 mRNA was detected in transfected cell culture by RT-
PCR whereas the presence of VP1 protein was confirmed
by indirect immunofluorescence assay (IFA) and western-
blotting. VP1 mRNA in transfected Vero cells was detected
by reverse transcription-polymerase chain reaction (RT-
PCR) at 48 hours post-transfection. However, the pres-
ence of VP1 mRNA is just a qualitative data and it cannot
reveal the level of VP1 expression, as the copy number of
target transcript was not determined. Real-time PCR anal-
ysis can be conducted in order to quantify the in vitro
expression level of VP1 gene in cell culture if necessary.
The VP1 protein expressed in cell culture was successfully
detected using Indirect Immunofluorescence Assay (IFA)
and Western blot method at 48 hours and 72 hours post-
transfection, respectively. The presence of VP1 protein
could not be detected with Western blotting at time points
earlier than 72 hours post-transfection, where this could
be due to low level of expression and thus insufficient
quantity of protein that can be detected. Comparatively,
Western blotting using colorimetric method is not as sen-
sitive as IFA, which utilises the aid of an optical instru-
ment (fluorescence microscope) for detection of target
protein. There are many possible reasons for low expres-
sion of an antigen, such as toxicity, poor codon usage, or
mRNA structure instability. It is also possible that the anti-
genic protein is unstable and rapidly degraded [20]. The
successful in vitro expression implies that the constructs
were able to direct VP1 protein synthesis correctly in
eukaryotic cells, thus confirming the functionality of the
constructs.
In order to assess the immune responses to DNA vaccine,
immunisation of female Balb/c mice was carried out using
intramuscular injection of the naked plasmid. Following
DNA immunisation, the antigenic proteins expressed
from plasmids especially for viral antigens seem to be
expressed, folded and assembled in the same manner as
when they are expressed during a natural viral infection.
As a result, the antigens are genuine with all the conforma-
tional epitopes required for protection being expressed
[21,22].
One of the major barriers to the development of an EV71
vaccine is the lack of a suitable animal model for the test-
ing of vaccine immunogenicity and efficacy. Laboratory
mice are only susceptible to EV71 infection in the first 4
days of life and become completely resistant by 6 days of
age [18,23]. EV71 infection caused no apparent clinical
Adjusted OD at 450 nm of ELISA for anti-VP1 IgG of mice serum collected at different time points at 1:50 dilution Figure 7
Adjusted OD at 450 nm of ELISA for anti-VP1 IgG of mice serum collected at different time points at 1:50 dilution.
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Virus neutralisation test of immunized mice seraon day 14 Figure 8
Virus neutralisation test of immunized mice seraon day 14. The neutralising activity of immunised mice sera against 
EV71 on day 14 was evaluated by virus neutralisation test using Vero cells. Figure 8a) and 8b) show almost 100% of CPE in 
Vero cells resulted by sera of mice immunized with pVAX1 and PBS (negative) respectively. Figure 8c) represents the virus 
control well with almost 100% CPE observed. Figure 8d) and 8e) showed the neutralizing activity of sera of mice immunized 
with pVAX1/VP1-S and pVAX1/VP1-4 respectively, where approximately 50% CPE was observed. Figure 8f) showed almost 
100% neutralization of EV71-infected human positive serum where no CPE was observed. Figure 8g) represents the normal 
Vero cells that are not infected with EV71. All the dilution of serum samples in Figure 8a) to 8f) was at 1:32 and microscopy 
examinations were carried out at 100× magnification. Arrows indicate the CPE.
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symptoms in all strains of adult mice tested, including
BALB/c, C3H, ICR, CD28 knock-out, and TNF-α receptor
knock-out mice [16]. Therefore, if further studies were to
be carried out in order to assess the protection against
lethal EV71 infection provided by the antibody elicited
following DNA vaccination, newborn mice have to be
challenged with enterovirus 71 and then followed by pas-
sive transfer of maternal antibody from immunised dams
to the newborn mice.
In the present study, the results of ELISA have confirmed
the immunogenicity of DNA vaccine constructs in elicit-
ing immune response in vivo with the presence of specific
anti-VP1 IgG in mice sera. Studies have shown that expres-
sion of genes from plasmids following injection into mus-
cles is optimal at 7–14 days post-injection [24]. In this
study, anti-VP1 IgG elicited by pVAX1/VP1-S and pVAX1/
VP1-4 increased to a very significant level on day 14 after
the first dose of injection. Following the first booster, the
anti-VP1 IgG in these two groups continued to increase to
a level with the highest OD value (Figure 6) but subse-
quently declined after the second booster. The decline of
IgG levels observed in this study might have been accom-
panied by an increase in cytolitic T cells. Tanghe et al. [25]
demonstrated that the antibody levels in mice immunised
with tuberculosis DNA vaccine decreased after the second
booster injection while an increase in IFN-γ and IL-2 levels
was detected. This observation showed a shift towards the
cellular immune response, which may provide an expla-
nation to the decline of anti-VP1 IgG levels observed in
the present study. However, this has to be confirmed by
further investigation.
From the results of the virus neutralisation assay, the anti-
VP1 IgG in the mice immunised with DNA vaccine con-
structs exhibited neutralising activity against EV71. How-
ever, the neutralising effect of EV71-infected human
positive serum was demonstrated to be much higher com-
pared with the sera of animals immunised with DNA vac-
cines. The possible explanation for this might be the
immune system of mice immunised with DNA vaccine
was only exposed to the antigenic epitopes that are found
in VP1 protein of EV71 while the EV71-infected human
had been exposed to all the various antigenic epitopes of
the whole EV71 virus particle. Therefore, the neutralising
antibodies produced by human immune system are able
to identify the wide range of various antigenic epitopes of
EV71 and thus possess higher neutralising effect. Another
possible reason could be that the confirmation of the pro-
tein synthesized by the plasmids may differ from that in
the live virus particles. Therefore, minor differences in the
confirmation of the antigenic epitopes could result in dif-
ferent neutralisation titres [26]. In this study, only mice
sera of day 14 post-immunisation (after a single dose of
vaccination) were tested for the neutralising activity, so
there is no further data to show the neutralisation titre
after the first and second booster vaccination. However,
studies have shown that neutralising antibodies were
developed after a first single-dose of DNA vaccination
with the neutralisation titre elevated and persisted for an
extended interval following booster injections [27-29].
Wu et al. (16) had reported that the neutralisation titre of
DNA vaccinated mice was still detectable at 32 weeks
post-immunisation and it also maintained a titre similar
to the one that immunised with inactivated virus.
pEGFPN1/VP1 which was provided by Prof. Dr. Sazaly
Abu Bakar (University Malaya) served as a positive control
in the vaccination experiment of the present study. This
construct has been shown to express VP1 protein in mice
after vaccination. The anti-VP1 IgG level of this group did
not show any statistically significant difference compared
to the negative control groups. It might be due to the fact
that the pEGFPN1 is not an expression vector that is spe-
cifically designed for DNA vaccination use, such as the
pVAX1 vector. Hence, pEGFPN1/VP1 is not as efficient as
pVAX1/VP1-S and pVAX1/VP1-4 in eliciting immune
response in mice.
Development of transgenic mice expressing the appropri-
ate human receptor molecule(s) for enterovirus 71 would
be the best and promising approach in order to under-
stand the pathogenesis of enterovirus encephalitis and to
test the candidate vaccines. This approach has been
extremely successful for poliovirus [30]. Since the receptor
The highest dilution of mice sera that resulted inmore than  50% CPE Figure 9
The highest dilution of mice sera that resulted 
inmore than 50% CPE. The sera of DNA vaccine groups 
(pVAX1/VP1-S and pVAX1/VP1-4) had resulted in approxi-
mately 50% CPE at a dilution of 1:32. Almost 100% CPE was 
observed in the sera of negative control groups (pVAX1 and 
PBS) at the dilution of 1:2 and the subsequent dilutions.
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for EV71 remains unknown, identification of the EV71
receptor is a major priority in vaccine research, as it will
allow the development of a transgenic mouse model for
studies of EV71 pathogenesis and vaccine efficacy.
5 Conclusion
Overall, this study has given promising results on genetic
immunisation with DNA vaccine encoding VP1 gene of
EV71. With further study and improvement, use of the
DNA vaccine might be a potential vaccine strategy against
EV71.
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